Axsome Therapeutics, Inc. (AXSM)
Axsome (AXSM) Q2 Loss Widens Y/Y, Revenues Beat Estimates
Axsome's (AXSM) bottom line declines year over year in the second quarter. Strong sales of Auvelity drive revenues.
Why Axsome Therapeutics Stock Is Sinking Today
Axsome's Q2 revenue beat estimates, but the company posted a wider net loss than expected. The primary culprit behind the disappointing bottom line were noncash charges of $26 million.
Axsome Therapeutics, Inc. (AXSM) Q2 2024 Earnings Call Transcript
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q2 2024 Earnings Conference Call August 5, 2024 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Pizzie - CFO Ari Maizel - EVP and Head, Commercial Conference Call Participants Vikram Purohit - Morgan Stanley Leonid Timashev - RBC Capital Markets Marc Goodman - Leerink Partners Charles Duncan - Cantor Fitzgerald Joon Lee - Truist Securities Raghuram Selvaraju - H.C. Wainwright Jason Gerberry - Bank of America Ami Fadia - Needham & Company Yatin Suneja - Guggenheim Partners David Amsellem - Piper Sandler Joel Beatty - Baird Joseph Thome - TD Cowen David Hoang - Citigroup Graig Suvannavejh - Mizuho Securities Ashwani Verma - UBS Myles Minter - William Blair Matt Kaplan - Ladenburg Thalmann Operator Hello, and welcome to the Axsome Therapeutics Second Quarter 2024 Financial Results Conference Call and Webcast.
Does Axsome (AXSM) Have the Potential to Rally 48.44% as Wall Street Analysts Expect?
The mean of analysts' price targets for Axsome (AXSM) points to a 48.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Axsome Therapeutics (AXSM) Reports Q2 Loss, Tops Revenue Estimates
Axsome Therapeutics (AXSM) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.30. This compares to loss of $1 per share a year ago.
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Biotech Stocks to Bet On Bright Industry Prospects
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position MRNA, SRPT, HALO, KRYS and AXSM well in this volatile sector.
Axsome Therapeutics: Lots Of Moving Parts
Today, we circle back to mid-cap biopharma Axsome Therapeutics, which has multiple potential catalysts on the horizon. The company has two approved products on the market and the potential to have six FDA approved drugs by the end of 2025. Analyst firms are largely positive on the shares, and explosive sales growth is projected over the next few years.
Wall Street Analysts Predict a 49.36% Upside in Axsome (AXSM): Here's What You Should Know
The mean of analysts' price targets for Axsome (AXSM) points to a 49.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
Vertex Pharmaceuticals and Axsome Therapeutics are moving toward key regulatory approvals. Thanks to solid tailwinds, both biotechs should handsomely reward investors over the long run.
The 3 Best Biotech Stocks to Buy in July 2024
Investing in biotech can be pretty unpredictable. Biotech stocks are highly volatile, and picking carefully can be the difference between losing all your capital and making unimaginable profits.
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
One of the critical components of the investing world is the proliferation and understanding of analyst predictions. That's because most retail investors prefer to research consumer information regarding stock picks through the calculations of those deemed more experienced in understanding financial fundamentals.
